FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100065401> ?p ?o ?g. }

• W2100065401 endingPage "375" @default.
• W2100065401 startingPage "367" @default.
• W2100065401 abstract "Background. Thrombin is a key enzyme in thrombogenesis. In animals, specific antithrombotic therapy at the time of coronary angioplasty reduced the incidence of subacute occlusion and inhibited the restenosis response. Argatroban is a highly selective synthetic thrombin antagonist that binds in a competitive manner. This is a report of a dose-verification study, assessing the safety and feasibility of intravenous Argatroban administration in patients undergoing percutaneous transluminal coronary angioplasty. Methods. Before angioplasty an intravenous bolus of 30 µg/kg argatroban was administered, followed by a continuous infusion of 3.5 µg/kg/min for 72 hours. Bolus injection was repeated, and the infusion rate was increased in order to achieve an activated coagulation time (ACT) of over 300 seconds. Following interim analysis, the bolus and initial infusion rate for the subsequent treatment groups was determined. Study endpoints were the occurrence of adverse events, coagulation tests, and qualitative angiogram reading. Patients were monitored by continuous 12-lead electrocardiographic recording over 24 hours, and underwent control angiography 18-24 hours following angioplasty. Results. Four treatment groups, comprised of 2, 8, 9, and 11 patients, respectively, were studied. The first two patients were excluded from analysis, since the initial dose was ineffective to attain an ACT-authorizing coronary angioplasty. The group with the highest dosage received a 250 µg/kg intravenous bolus of argatroban, followed by a 4 hour infusion of 15 µg/kg/min. At 4 hours the infusion rate was lowered to 3.8 µg/kg/min and was continued for 68 hours without adjustment for catheter removal. The adverse event profile included myocardial infarction, aortocoronary bypass graft, bailout procedures, and repeat coronary angioplasty. Thrombin-time (TT), activated partial thromboplastin time (APTT), and prothrombin time (PT) were significantly related to argatroban plasma concentration, as demonstrated by regression analyses (R-square 0.64, 0.71, and 0.84, respectively). Prothrombin fragments 1 and 2 and thrombin-antithrombin III complex did not fit into a mathematical model, but showed slightly increased levels after reduction or cessation of the infusion rate. Conclusions. This dose-verification study, including 30 patients at four dose levels, indicated that argatroban infusion in coronary angioplasty patients can be administered safely, and results in an adequate and predictable level of anticoagulation." @default.
• W2100065401 created "2016-06-24" @default.
• W2100065401 creator A5015479782 @default.
• W2100065401 creator A5034488968 @default.
• W2100065401 creator A5052083632 @default.
• W2100065401 creator A5061524536 @default.
• W2100065401 creator A5071200882 @default.
• W2100065401 creator A5071630648 @default.
• W2100065401 date "1996-12-01" @default.
• W2100065401 modified "2023-09-27" @default.
• W2100065401 title "Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study" @default.
• W2100065401 cites W1971064056 @default.
• W2100065401 cites W1978631764 @default.
• W2100065401 cites W1979698812 @default.
• W2100065401 cites W1980796989 @default.
• W2100065401 cites W1991189950 @default.
• W2100065401 cites W1993330838 @default.
• W2100065401 cites W1995798630 @default.
• W2100065401 cites W1998839295 @default.
• W2100065401 cites W1998955571 @default.
• W2100065401 cites W2002999246 @default.
• W2100065401 cites W2016642690 @default.
• W2100065401 cites W2020906145 @default.
• W2100065401 cites W2021314204 @default.
• W2100065401 cites W2021407245 @default.
• W2100065401 cites W2024342314 @default.
• W2100065401 cites W2032277753 @default.
• W2100065401 cites W2034863939 @default.
• W2100065401 cites W2046027264 @default.
• W2100065401 cites W2050032102 @default.
• W2100065401 cites W2050629576 @default.
• W2100065401 cites W2051119555 @default.
• W2100065401 cites W2053913287 @default.
• W2100065401 cites W2056717885 @default.
• W2100065401 cites W2076130949 @default.
• W2100065401 cites W2081769864 @default.
• W2100065401 cites W2085916658 @default.
• W2100065401 cites W2093721884 @default.
• W2100065401 cites W2095134554 @default.
• W2100065401 cites W2106349347 @default.
• W2100065401 cites W2159642184 @default.
• W2100065401 cites W2169838114 @default.
• W2100065401 cites W2274445622 @default.
• W2100065401 cites W2314358062 @default.
• W2100065401 cites W4235858444 @default.
• W2100065401 cites W2024048385 @default.
• W2100065401 doi "https://doi.org/10.1007/bf00133080" @default.
• W2100065401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10602566" @default.
• W2100065401 hasPublicationYear "1996" @default.
• W2100065401 type Work @default.
• W2100065401 sameAs 2100065401 @default.
• W2100065401 citedByCount "32" @default.
• W2100065401 countsByYear W21000654012012 @default.
• W2100065401 countsByYear W21000654012013 @default.
• W2100065401 crossrefType "journal-article" @default.
• W2100065401 hasAuthorship W2100065401A5015479782 @default.
• W2100065401 hasAuthorship W2100065401A5034488968 @default.
• W2100065401 hasAuthorship W2100065401A5052083632 @default.
• W2100065401 hasAuthorship W2100065401A5061524536 @default.
• W2100065401 hasAuthorship W2100065401A5071200882 @default.
• W2100065401 hasAuthorship W2100065401A5071630648 @default.
• W2100065401 hasBestOaLocation W21000654012 @default.
• W2100065401 hasConcept C126322002 @default.
• W2100065401 hasConcept C164705383 @default.
• W2100065401 hasConcept C2777292125 @default.
• W2100065401 hasConcept C2777557582 @default.
• W2100065401 hasConcept C2777987278 @default.
• W2100065401 hasConcept C2778283817 @default.
• W2100065401 hasConcept C2778583881 @default.
• W2100065401 hasConcept C2779612170 @default.
• W2100065401 hasConcept C2780326628 @default.
• W2100065401 hasConcept C42219234 @default.
• W2100065401 hasConcept C43376680 @default.
• W2100065401 hasConcept C71924100 @default.
• W2100065401 hasConcept C89560881 @default.
• W2100065401 hasConceptScore W2100065401C126322002 @default.
• W2100065401 hasConceptScore W2100065401C164705383 @default.
• W2100065401 hasConceptScore W2100065401C2777292125 @default.
• W2100065401 hasConceptScore W2100065401C2777557582 @default.
• W2100065401 hasConceptScore W2100065401C2777987278 @default.
• W2100065401 hasConceptScore W2100065401C2778283817 @default.
• W2100065401 hasConceptScore W2100065401C2778583881 @default.
• W2100065401 hasConceptScore W2100065401C2779612170 @default.
• W2100065401 hasConceptScore W2100065401C2780326628 @default.
• W2100065401 hasConceptScore W2100065401C42219234 @default.
• W2100065401 hasConceptScore W2100065401C43376680 @default.
• W2100065401 hasConceptScore W2100065401C71924100 @default.
• W2100065401 hasConceptScore W2100065401C89560881 @default.
• W2100065401 hasIssue "4" @default.
• W2100065401 hasLocation W21000654011 @default.
• W2100065401 hasLocation W21000654012 @default.
• W2100065401 hasLocation W21000654013 @default.
• W2100065401 hasOpenAccess W2100065401 @default.
• W2100065401 hasPrimaryLocation W21000654011 @default.
• W2100065401 hasRelatedWork W1979061561 @default.
• W2100065401 hasRelatedWork W2018983290 @default.
• W2100065401 hasRelatedWork W2092972260 @default.
• W2100065401 hasRelatedWork W2100065401 @default.

• next